Protective Effects of Ticagrelor on Myocardial Injury after Infarction

Circulation

Volumn 134, Issue 22, 2016, Pages 1708-1719

  Vilahur, Gemma ^a   Gutiérrez, Manuel ^b   Casani, Laura ^a   Varela, Lourdes ^a   Capdevila, Antoni ^b   Pons Lladó, Guillem ^b   Carreras, Francesc ^b   Carlsson, Leif ^c   Hidalgo, Alberto ^b   Badimon, Lina ^a,d  

^a Institut Català de Ciències Cardiovasculars   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

cardiac imaging techniques; cardioprotection; edema; myocardial infarction; purinergic P2Y receptor antagonists

Indexed keywords

8 (4 SULFOPHENYL)THEOPHYLLINE; AQUAPORIN 4; CD36 ANTIGEN; CLOPIDOGREL; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PLACEBO; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; CARDIOTONIC AGENT; TICLOPIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC MUSCLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EDEMA; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART INFARCTION; HEART LEFT VENTRICLE; HEART MUSCLE INJURY; HEART PROTECTION; LOADING DRUG DOSE; NONHUMAN; PORCINE MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PIG; RANDOMIZATION; THROMBOCYTE;

ADENOSINE; ANIMALS; BLOOD PLATELETS; CARDIOTONIC AGENTS; CYCLOOXYGENASE 2; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RANDOM ALLOCATION; SWINE; TICLOPIDINE;

EID: 84992699816     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.024014     Document Type: Article

References (50)

1. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
2. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913. doi: 10. 1161/01. CIR. 0000072771. 11429. 83.
3. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. doi: 10. 1056/NEJMoa0904327.
4. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. doi: 10. 1056/NEJMoa0706482.
5. Abergel E, Nikolsky E. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag. 2010;6:963-977. doi: 10. 2147/VHRM. S13263.
6. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-1800. doi: 10. 1056/NEJMoa1500857.
7. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038-1047. doi: 10. 1093/eurheartj/ehi754.
8. Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation. 2013;127:673-680. doi: 10. 1161/ CIRCULATIONAHA. 112. 124248.
9. Varenhorst C, Alström U, Braun OÖ, Storey RF, Mahaffey KW, Bertilsson M, Cannon CP, Scirica BM, Himmelmann A, James SK, Wallentin L, Held C. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart. 2014;100:1762-1769. doi: 10. 1136/heartjnl-2014-305619.
10. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, Sabatine MS, Steg PG. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67:2732-2740. doi: 10. 1016/j. jacc. 2016. 03. 529.
11. Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19:209-219. doi: 10. 1177/1074248413511693.
12. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007;14:1315-1323. doi: 10. 1038/sj. cdd. 4402132.
13. Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63:2503-2509. doi: 10. 1016/j. jacc. 2014. 03. 031.
14. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM; INFUSE-AMI Investigators. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307:1817-1826. doi: 10. 1001/ jama. 2012. 421.
15. Roubille F, Lairez O, Mewton N, Rioufol G, Ranc S, Sanchez I, Cung TT, Elbaz M, Piot C, Ovize M. Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis. Basic Res Cardiol. 2012;107:275. doi: 10. 1007/ s00395-012-0275-3.
16. Nanhwan MK, Ling S, Kodakandla M, Nylander S, Ye Y, Birnbaum Y. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014;34:2078-2085. doi: 10. 1161/ ATVBAHA. 114. 304002.
17. McVey MJ, Smits GJ, Cox BF, Kitzen JM, Clark KL, Perrone MH. Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: coronary hemodynamic and cardioprotective effects in the canine myocardium. J Cardiovasc Pharmacol. 1999;33:703-710.
18. Vilahur G, Gutiérrez M, Casaní L, Cubedo J, Capdevila A, Pons-Llado G, Carreras F, Hidalgo A, Badimon L. Hypercholesterolemia abolishes high-density lipoprotein-related cardioprotective effects in the setting of myocardial infarction. J Am Coll Cardiol. 2015;66:2469-2470. doi: 10. 1016/j. jacc. 2015. 08. 901.
19. Garcia-Dorado D, Andres-Villarreal M, Ruiz-Meana M, Inserte J, Barba I. Myocardial edema: a translational view. J Mol Cell Cardiol. 2012;52:931-939. doi: 10. 1016/j. yjmcc. 2012. 01. 010.
20. Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, Bollen AW, Chan P, Verkman AS. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med. 2000;6:159-163. doi: 10. 1038/72256.
21. Castanares-Zapatero D, Bouleti C, Sommereyns C, Gerber B, Lecut C, Mathivet T, Horckmans M, Communi D, Foretz M, Vanoverschelde JL, Germain S, Bertrand L, Laterre PF, Oury C, Viollet B, Horman S, Beauloye C. Connection between cardiac vascular permeability, myocardial edema, and inflammation during sepsis: role of the ?1AMP-activated protein kinase isoform. Crit Care Med. 2013;41:e411-e422. doi: 10. 1097/ CCM. 0b013e31829866dc.
22. Kim TT, Dyck JR. Is AMPK the savior of the failing heart? Trends Endocrinol Metab. 2015;26:40-48. doi: 10. 1016/j. Tem. 2014. 11. 001.
23. Ye Y, Birnbaum GD, Perez-Polo JR, Nanhwan MK, Nylander S, Birnbaum Y. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol. 2015;35:1805-1814. doi: 10. 1161/ATVBAHA. 115. 305655.
24. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65:1454-1471. doi: 10. 1016/j. jacc. 2015. 02. 032.
25. Lecour S, Bøtker HE, Condorelli G, Davidson SM, Garcia-Dorado D, Engel FB, Ferdinandy P, Heusch G, Madonna R, Ovize M, Ruiz-Meana M, Schulz R, Sluijter JP, Van Laake LW, Yellon DM, Hausenloy DJ. ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res. 2014;104:399-411. doi: 10. 1093/cvr/cvu225.
26. Piper HM, García-Dorado D. Prime causes of rapid cardiomyocyte death during reperfusion. Ann Thorac Surg. 1999;68:1913-1919.
27. Rutkovskiy A, Stensløkken KO, Mariero LH, Skrbic B, Amiry-Moghaddam M, Hillestad V, Valen G, Perreault MC, Ottersen OP, Gullestad L, Dahl CP, Vaage J. Aquaporin-4 in the heart: expression, regulation and functional role in ischemia. Basic Res Cardiol. 2012;107:280. doi: 10. 1007/s00395-012-0280-6.
28. Warth A, Eckle T, Köhler D, Faigle M, Zug S, Klingel K, Eltzschig HK, Wolburg H. Upregulation of the water channel aquaporin-4 as a potential cause of postischemic cell swelling in a murine model of myocardial infarction. Cardiology. 2007;107:402-410. doi: 10. 1159/000099060.
29. Zhang HZ, Kim MH, Lim JH, Bae HR. Time-dependent expression patterns of cardiac aquaporins following myocardial infarction. J Korean Med Sci. 2013;28:402-408. doi: 10. 3346/ jkms. 2013. 28. 3. 402.
30. Lee MR, Ruby CL, Hinton DJ, Choi S, Adams CA, Young Kang N, Choi DS. Striatal adenosine signaling regulates EAAT2 and astrocytic AQP4 expression and alcohol drinking in mice. Neuropsychopharmacology. 2013;38:437-445. doi: 10. 1038/ npp. 2012. 198.
31. Hinton DJ, Lee MR, Jang JS, Choi DS. Type 1 equilibrative nucleoside transporter regulates astrocyte-specific glial fibrillary acidic protein expression in the striatum. Brain Behav. 2014;4:903-914. doi: 10. 1002/brb3. 283.
32. Galaup A, Gomez E, Souktani R, Durand M, Cazes A, Monnot C, Teillon J, Le Jan S, Bouleti C, Briois G, Philippe J, Pons S, Martin V, Assaly R, Bonnin P, Ratajczak P, Janin A, Thurston G, Valenzuela DM, Murphy AJ, Yancopoulos GD, Tissier R, Berdeaux A, Ghaleh B, Germain S. Protection against myocardial infarction and noreflow through preservation of vascular integrity by angiopoietinlike 4 Circulation. 2012;125:140-149. doi: 10. 1161/CIRCULATIONAHA. 111. 049072.
33. Escobar DA, Botero-Quintero AM, Kautza BC, Luciano J, Loughran P, Darwiche S, Rosengart MR, Zuckerbraun BS, Gomez H. Adenosine monophosphate-activated protein kinase activation protects against sepsis-induced organ injury and inflammation. J Surg Res. 2015;194:262-272. doi: 10. 1016/j. jss. 2014. 10. 009.
34. Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, Husted SE, Cannon CP, Becker RC, Steg PG, Åsenblad N, Wallentin L. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets. 2014;25:517-525. doi: 10. 3109/09537104. 2013. 842965.
35. Peleli M, Hezel M, Zollbrecht C, Persson AE, Lundberg JO, Weitzberg E, Fredholm BB, Carlström M. In adenosine A2B knockouts acute treatment with inorganic nitrate improves glucose disposal, oxidative stress, and AMPK signaling in the liver. Front Physiol. 2015;6:222. doi: 10. 3389/fphys. 2015. 00222.
36. Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63:872-877 doi:10. 1016/j. jacc. 2013. 09. 067
37. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015;116:674-699. doi: 10. 1161/CIRCRESAHA. 116. 305348.
38. Thuny F, Lairez O, Roubille F, Mewton N, Rioufol G, Sportouch C, Sanchez I, Bergerot C, Thibault H, Cung TT, Finet G, Argaud L, Revel D, Derumeaux G, Bonnefoy-Cudraz E, Elbaz M, Piot C, Ovize M, Croisille P. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59:2175-2181. doi: 10. 1016/j. jacc. 2012. 03. 026.
39. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006;27:2400-2405. doi: 10. 1093/ eurheartj/ehl094.
40. Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C, Ganame J, Dymarkowski S, Janssens S, Belmans A, Van de Werf F. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2011;32:867-877. doi: 10. 1093/eurheartj/ ehq492.
41. Janssens GN, van Leeuwen MA, van der Hoeven NW, de Waard GA, Nijveldt R, Diletti R, Zijlstra F, von Birgelen C, Escaned J, Valgimigli M, van Royen N. Reducing microvascular dysfunction in revascularized patients with ST-elevation myocardial infarction by off-target properties of ticagrelor versus prasugrel. Rationale and design of the REDUCE-MVI Study. J Cardiovasc Transl Res. 2016;9:249-256. doi: 10. 1007/s12265-016-9691-3.
42. Merla R, Ye Y, Lin Y, Manickavasagam S, Huang MH, Perez-Polo RJ, Uretsky BF, Birnbaum Y. The central role of adenosine in statininduced erk1/2, akt, and enos phosphorylation. Am J Physiol Heart Circ Physiol. 2007;293:H1918-H1928 doi:10. 1152/ajpheart. 00416. 2007
43. Bolli R, Shinmura K, Tang XL, Kodani E, Xuan YT, Guo Y, Dawn B. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 2002;55:506-519.
44. Velders MA, Abtan J, Angiolillo DJ, Ardissino D, Harrington RA, Hellkamp A, Himmelmann A, Husted S, Katus HA, Meier B, Schulte PJ, Storey RF, Wallentin L, Gabriel Steg P, James SK; PLATO Investigators. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart. 2016;102:617-625. doi: 10. 1136/heartjnl-2015-308963.
45. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544-554. doi: 10. 1161/CIRCULATIONAHA. 111. 047498.
46. Bonaca MP, Bhatt DL, Oude Ophuis T, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Theroux P, Hamm C, Spinar J, Kiss RG, Dalby AJ, Medina FA, Kontny F, Aylward PE, Jensen EC, Held P, Braunwald E, Sabatine MS. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial. JAMA Cardiol. 2016;1:425-432 doi:10. 1001/jamacardio. 2016. 1017
47. Kidambi A, Mather AN, Swoboda P, Motwani M, Fairbairn TA, Greenwood JP, Plein S. Relationship between myocardial edema and regional myocardial function after reperfused acute myocardial infarction: an MR imaging study. Radiology. 2013;267:701-708. doi: 10. 1148/radiol. 12121516.
48. Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, Penn MS. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost. 2010;104:609-617. doi: 10. 1160/ TH09-12-0823.
49. Fernández-Jiménez R, Sánchez-González J, Agüero J, García-Prieto J, López-Martín GJ, García-Ruiz JM, Molina-Iracheta A, Rosselló X, Fernández-Friera L, Pizarro G, García-Álvarez A, Dall'Armellina E, Macaya C, Choudhury RP, Fuster V, Ibáñez B. Myocardial edema after ischemia/reperfusion is not stable and follows a bimodal pattern: imaging and histological tissue characterization. J Am Coll Cardiol. 2015;65:315-323. doi: 10. 1016/j. jacc. 2014. 11. 004.
50. Horneffer PJ, Healy B, Gott VL, Gardner TJ. The rapid evolution of a myocardial infarction in an end-artery coronary preparation. Circulation. 1987;76(5 pt 2):V39-V42.